Synlogic is a clinical-stage biopharmaceutical company focused on improving its drug discovery and development platform for Synthetic Biotic? medicines, which are designed using synthetic biology to genetically reprogram beneficial microbes to treat metabolic and inflammatory diseases and cancer. SYNB1020, the company's first therapeutic program, is an oral therapy for the treatment of patients with liver disease and hepatic encephalopathy and in patients with urea cycle disorders. SYNB1618, its second program, is an oral therapy intended for the treatment of phenylketonuria, an inborn errors of metabolism in which the amino acid phenylalanine accumulates in the body as a result of genetic defects.
  • TickerSYBX
  • ISINUS87166L1008
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for SYBX

ValuEngine Rating and Forecast Report for SYBX

David Nierengarten ...
  • Jeffrey La Rosa

1Q:19 Financials, Oral Formulation for ‘1618 Forthcoming

ValuEngine Rating and Forecast Report for SYBX

ValuEngine Rating and Forecast Report for SYBX

David Nierengarten ...
  • Jeffrey La Rosa

1Q:19 Financials, Oral Formulation for ‘1618 Forthcoming

David Nierengarten ...
  • Jeffrey La Rosa

‘Solid’ Developments in SYNB1618 Product Formulation

ValuEngine Rating and Forecast Report for SYBX

ValuEngine Rating and Forecast Report for SYBX

ValuEngine Rating and Forecast Report for SYBX

ValuEngine Rating and Forecast Report for SYBX

ValuEngine Rating and Forecast Report for SYBX

ValuEngine Rating and Forecast Report for SYBX

ValuEngine Rating and Forecast Report for SYBX

ValuEngine Rating and Forecast Report for SYBX

ValuEngine Rating and Forecast Report for SYBX

ValuEngine Rating and Forecast Report for SYBX

ResearchPool Subscriptions

Get the most out of your insights

Get in touch